Introduction to special issue

Biotechnology: The Genomics Gamble

Science  07 Feb 1997:
Vol. 275, Issue 5301, pp. 767-772
DOI: 10.1126/science.275.5301.767

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

Drug companies, biotechs, and Wall Street investors are putting their money down on efforts to unlock the secrets of human DNA. But when will genomics deliver on its promise of next-generation drugs and treatments?

RELATED WEB SITES:

http://www.ornl.gov/sci/techresources/Human_Genome/home.htmlA U.S. government-maintained Web page for news, policy guidelines, and ethics discussions centered on the international Human Genome Project.

http://www3.techstocks.com/~wsapi/investor/stocktalk-10A private site where small investors chat, often with scant insight, about a wide variety of biotech stocks.

http://www.tradesmart.com/rumor/The Biotech Rumor Mill, a gossip zone about biotech companies, much of it anonymous. (See the site review in Science's Next Wave.)

http://www.recap.com/Recombinant Capital, a San Francisco consulting group directed by Mark Edwards. With detailed analytical information on biotech companies, their capitalization, and past press releases.

http://www.sec.gov/cgi-bin/srch-edgarThe U.S. Securities and Exchange Commission's search engine for looking up recent disclosures filed by public companies.

Related Content